|
|
胰高血糖素样肽-1受体激动剂治疗心力衰竭的研究进展
|
Abstract:
心力衰竭(Heart Failure, HF)病理生理机制复杂，治疗选择有限，是全球心血管疾病的重要负担。作为代谢性疾病的治疗药物，胰高血糖素样肽-1受体激动剂(GLP-1RA)近年来被发现对心血管的保护作用显著，为预防和治疗心力衰竭提供了新的方向。本文将对GLP-1RA治疗心力衰竭的研究进展作一综述。
Heart failure (HF) has complex pathophysiological mechanisms and limited treatment options, serving as a significant burden of cardiovascular diseases worldwide. As therapeutic agents for metabolic diseases, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been found to exert remarkable cardiovascular protective effects in recent years, providing a new direction for the prevention and treatment of heart failure. This article reviews the research progress of GLP-1RAs in the treatment of heart failure.
| [1] | Ponikowski, P., Anker, S.D., AlHabib, K.F., Cowie, M.R., Force, T.L., Hu, S., et al. (2014) Heart Failure: Preventing Disease and Death Worldwide. ESC Heart Failure, 1, 4-25. https://doi.org/10.1002/ehf2.12005 |
| [2] | Dunlay, S.M., Roger, V.L. and Redfield, M.M. (2017) Epidemiology of Heart Failure with Preserved Ejection Fraction. Nature Reviews Cardiology, 14, 591-602. https://doi.org/10.1038/nrcardio.2017.65 |
| [3] | Wang, H., Chai, K., Du, M., Wang, S., Cai, J., Li, Y., et al. (2021) Prevalence and Incidence of Heart Failure among Urban Patients in China: A National Population-Based Analysis. Circulation: Heart Failure, 14, e008406. https://doi.org/10.1161/circheartfailure.121.008406 |
| [4] | Drucker, D.J. and Nauck, M.A. (2006) The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes. The Lancet, 368, 1696-1705. https://doi.org/10.1016/s0140-6736(06)69705-5 |
| [5] | 李兴红, 金春娜. 新型降糖药物SGLT2抑制剂和GLP-1受体激动剂的心血管获益研究进展[J]. 心电与循环, 2024, 43(5): 524-529. |
| [6] | Kosiborod, M.N., Abildstrøm, S.Z., Borlaug, B.A., Butler, J., Rasmussen, S., Davies, M., et al. (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 389, 1069-1084. https://doi.org/10.1056/nejmoa2306963 |
| [7] | Drucker, D.J. (2018) Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Cell Metabolism, 27, 740-756. https://doi.org/10.1016/j.cmet.2018.03.001 |
| [8] | Davies, M., Færch, L., Jeppesen, O.K., Pakseresht, A., Pedersen, S.D., Perreault, L., et al. (2021) Semaglutide 2∙4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial. The Lancet, 397, 971-984. https://doi.org/10.1016/s0140-6736(21)00213-0 |
| [9] | Iacobellis, G. and Villasante Fricke, A.C. (2020) Effects of Semaglutide versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity. Journal of the Endocrine Society, 4, bvz042. https://doi.org/10.1210/jendso/bvz042 |
| [10] | Gaspari, T., Brdar, M., Lee, H.W., Spizzo, I., Hu, Y., Widdop, R.E., et al. (2015) Molecular and Cellular Mechanisms of Glucagon-Like Peptide-1 Receptor Agonist-Mediated Attenuation of Cardiac Fibrosis. Diabetes and Vascular Disease Research, 13, 56-68. https://doi.org/10.1177/1479164115605000 |
| [11] | Ban, K., Noyan-Ashraf, M.H., Hoefer, J., Bolz, S., Drucker, D.J. and Husain, M. (2008) Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated through Both Glucagon-Like Peptide 1 Receptor-Dependent and-Independent Pathways. Circulation, 117, 2340-2350. https://doi.org/10.1161/circulationaha.107.739938 |
| [12] | Nikolaidis, L.A., et al. (2004) Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs with Pacing-Induced Dilated Cardiomyopathy. Circulation, 110, 955-961. https://doi.org/10.1161/01.CIR.0000139339.85840.DD |
| [13] | Kim, M., Platt, M.J., Shibasaki, T., Quaggin, S.E., Backx, P.H., Seino, S., et al. (2013) GLP-1 Receptor Activation and Epac2 Link Atrial Natriuretic Peptide Secretion to Control of Blood Pressure. Nature Medicine, 19, 567-575. https://doi.org/10.1038/nm.3128 |
| [14] | Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F.E., Nauck, M.A., et al. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375, 311-322. https://doi.org/10.1056/nejmoa1603827 |
| [15] | Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., Diaz, R., Lakshmanan, M., Pais, P., et al. (2019) Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial. The Lancet, 394, 121-130. https://doi.org/10.1016/s0140-6736(19)31149-3 |
| [16] | Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jódar, E., Leiter, L.A., et al. (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375, 1834-1844. https://doi.org/10.1056/nejmoa1607141 |
| [17] | Kosiborod, M.N., Abildstrøm, S.Z., Borlaug, B.A., Butler, J., Rasmussen, S., Davies, M., et al. (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 389, 1069-1084. https://doi.org/10.1056/nejmoa2306963 |
| [18] | Kosiborod, M.N., Petrie, M.C., Borlaug, B.A., Butler, J., Davies, M.J., Hovingh, G.K., et al. (2024) Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. New England Journal of Medicine, 390, 1394-1407. https://doi.org/10.1056/nejmoa2313917 |
| [19] | Butler, J., Shah, S.J., Petrie, M.C., Borlaug, B.A., Abildstrøm, S.Z., Davies, M.J., et al. (2024) Semaglutide versus Placebo in People with Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the Step-STEP-HFpEF and STEP-HFpEF DM Randomised Trials. The Lancet, 403, 1635-1648. https://doi.org/10.1016/s0140-6736(24)00469-0 |
| [20] | Solomon, S.D., Ostrominski, J.W., Wang, X., Shah, S.J., Borlaug, B.A., Butler, J., et al. (2024) Effect of Semaglutide on Cardiac Structure and Function in Patients with Obesity-Related Heart Failure. Journal of the American College of Cardiology, 84, 1587-1602. https://doi.org/10.1016/j.jacc.2024.08.021 |
| [21] | Lincoff, A.M., Brown-Frandsen, K., Colhoun, H.M., Deanfield, J., Emerson, S.S., Esbjerg, S., et al. (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389, 2221-2232. https://doi.org/10.1056/nejmoa2307563 |
| [22] | Kittipibul, V. and Mentz, R.J. (2024) Effects of GLP-1 Receptor Agonists on Heart Failure Outcomes: The FLOW of Evidence. Journal of the American College of Cardiology, 84, 1629-1631. https://doi.org/10.1016/j.jacc.2024.08.016 |
| [23] | Margulies, K.B., Hernandez, A.F., Redfield, M.M., Givertz, M.M., Oliveira, G.H., Cole, R., et al. (2016) Effects of Liraglutide on Clinical Stability among Patients with Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA, 316, 500-508. https://doi.org/10.1001/jama.2016.10260 |
| [24] | Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R.S., Nielsen, R., Hänselmann, A., et al. (2016) Effect of Liraglutide, a Glucagon‐Like Peptide‐1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes (Live)—A Multicentre, Double‐Blind, Randomised, Placebo‐Controlled Trial. European Journal of Heart Failure, 19, 69-77. https://doi.org/10.1002/ejhf.657 |
| [25] | Abel, E.D. (2005) Myocardial Insulin Resistance and Cardiac Complications of Diabetes. Current Drug Targets-Immune, Endocrine & Metabolic Disorders, 5, 219-226. https://doi.org/10.2174/1568008054064869 |
| [26] | Scirica, B.M., Braunwald, E., Raz, I., Cavender, M.A., Morrow, D.A., Jarolim, P., et al. (2014) Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Circulation, 130, 1579-1588. https://doi.org/10.1161/circulationaha.114.010389 |
| [27] | Ussher, J.R. and Drucker, D.J. (2014) Cardiovascular Actions of Incretin-Based Therapies. Circulation Research, 114, 1788-1803. https://doi.org/10.1161/circresaha.114.301958 |
| [28] | Pratley, R.E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., et al. (2010) Liraglutide versus Sitagliptin for Patients with Type 2 Diabetes Who Did Not Have Adequate Glycaemic Control with Metformin: A 26-Week, Randomised, Parallel-Group, Open-Label Trial. The Lancet, 375, 1447-1456. https://doi.org/10.1016/s0140-6736(10)60307-8 |
